Biological Psychiatry
Volume 65, Issue 7 , Pages 600-606 , 1 April 2009

A Double-Blind, Placebo-Controlled Study of the Opiate Antagonist, Naltrexone, in the Treatment of Kleptomania

  • Jon E. Grant

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jon E. Grant, J.D., M.D., M.P.H., Department of Psychiatry, University of Minnesota School of Medicine, 2450 Riverside Avenue, Minneapolis, MN 55454
    • ,
  • Suck Won Kim
    • ,
  • Brian L. Odlaug

Received 8 September 2008 ,Revised 20 November 2008 ,Accepted 20 November 2008.

References 

  1. McElroy SL, Pope HG, Hudson JI, Keck PE, White KL. Kleptomania: A report of 20 cases. Am J Psychiatry. 1991;148:652–657
  2. Aboujaoude E, Gamel N, Koran LM. Overview of kleptomania and phenomenological description of 40 patients. Prim Care Companion J Clin Psychiatry. 2004;6:244–247
  3. Goldman MJ. Kleptomania: Making sense of the nonsensical. Am J Psychiatry. 1991;148:986–996
  4. Grant JE, Kim SW. Clinical characteristics and associated psychopathology of 22 patients with kleptomania. Compr Psychiatry. 2002;43:378–384
  5. Grant JE, Potenza MN. Gender-related differences in individuals seeking treatment for kleptomania. CNS Spectr. 2008;13:235–245
  6. National Association for Shoplifting Prevention. Shoplifting statistics. 2006;http://www.shopliftingprevention.org/WhatNASPOffers/NRC/PublicEducStats.htmAccessed July 25, 2008
  7. Blanco C, Grant J, Petry NM, Simpson HB, Alegria A, Liu SM, et al. Prevalence and correlates of shoplifting in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Am J Psychiatry. 2008;165:905–913
  8. Odlaug BL, Grant JE. Prevalence of impulse control disorders in a college sample. 2008;Presented at the Annual Meeting of the American Psychiatric Association, May 2008, Washington, DC. NR2-069 [poster]
  9. Grant JE, Levine L, Kim D, Potenza MN. Prevalence of impulse control disorders in adult psychiatric inpatients. Am J Psychiatry. 2005;162:2184–2188
  10. Lejoyeux M, Feuché N, Loi S, Solomon J, Adès J. Study of impulse-control disorders among alcohol-dependent patients. J Clin Psychiatry. 1999;60:302–305
  11. Lejoyeux M, Arbaretaz M, McLoughlin M, Adès J. Impulse control disorders and depression. J Nerv Ment Dis. 2002;190:310–314
  12. Esquirol E. Des Maladies Mentales. Paris: Bailliere; 1838;
  13. Grant JE, Odlaug BL. Kleptomania: Clinical characteristics and treatment. Rev Bras Psiquiatr. 2008;30(suppl 1):S11–S15
  14. Grant JE. Family history and psychiatric comorbidity in persons with kleptomania. Compr Psychiatry. 2003;44(6):437–441
  15. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876–880
  16. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am J Psychiatry. 1999;156:1758–1764
  17. Martin WR, Jasinski D, Mansky P. Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry. 1973;23:784–789
  18. Kosten TR, Kleber HD, Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 1989;44:887–892
  19. Ikemoto S, Glazier BS, Murphy JM, McBride WJ. Role of dopamine D1 and D2 receptors in the nucleus accumbens in mediating reward. J Neurosci. 1997;17:8580–8587
  20. Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001;49:914–921
  21. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56:719–724
  22. Stewart J. Reinstatement of heroin and cocaine self-administration behavior in the rat by intracerebral application of morphine in the ventral tegmental area. Pharmacol Biochem Behav. 1984;20:917–923
  23. Matthews RT, German DC. Electrophysiological evidence for excitation of rat ventral tegmental area dopamine neurons by morphine. Neuroscience. 1984;11:617–625
  24. Broekkamp CL, Phillips AG. Facilitation of self-stimulation behavior following intracerebral microinjections of opioids into the ventral tegmental area. Pharmacol Biochem Behav. 1979;11:289–295
  25. Grant JE, Kim SW. An open label study of naltrexone in the treatment of kleptomania. J Clin Psychiatry. 2002;63:349–356
  26. Koran LM, Aboujaoude EN, Gamel NN. Escitalopram treatment of kleptomania: An open-label trial followed by double-blind discontinuation. J Clin Psychiatry. 2007;68:422–427
  27. Matthews RT, German DC. Electrophysiological evidence for excitation of rat ventral tegmental area and dopamine neurons by morphine. Neuroscience. 1984;11:617–625
  28. Stewart J. Reinstatement of heroin and cocaine self-administration behavior in the rat by intracerebral application of morphine in the ventral tegmental area. Pharmacol Biochem Behav. 1984;20:917–923
  29. Grant JE, Kim SW, McCabe J. Structured Clinical Interview for Kleptomania (SCI-K): Peliminary validity and reliability testing. Int J Methods Psychiatr Res. 2006;15:83–94
  30. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62
  31. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–55
  32. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-Patient Edition. New York: Biometrics Research Department, New York State Psychiatric Institute (SCID-I/P, Version 2.0); 1995;
  33. Sheehan DV. The Anxiety Disease. New York: Scribner's; 1983;
  34. Kim SW. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry. 1998;59:159–164
  35. Grant JE, Kim SW, Hartman BK. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008;69:783–789
  36. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Maryland: National Institute of Mental Health. U.S. Dept Health, Education and Welfare publication (ADM); 1976;76–338, 218–222
  37. Davison AC, Hinkley DV. Bootstrap Methods and Their Application. Cambridge, United Kingdom: Cambridge University Press; 1997;
  38. Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006;163:303–312
  39. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999;56:719–724
  40. Anton RF, O'Malley SS, Ciraulo CC, Cisler RA, Couper D, Donovan DM, et al. COMBINE Study Research Group Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA. 2006;295:2003–2017
  41. Potenza MN. Should addictive disorders include non-substance-related conditions?. Addiction. 2006;101(suppl 1):142–151
  42. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: A meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2005;8:267–280
  43. Grant JE. Outcome study of kleptomania patients treated with naltrexone: A chart review. Clin Neuropharmacol. 2005;28:11–14
  44. Dannon PN, Lowengrub KM, Iancu I, Kotler M. Kleptomania: Comorbid psychiatric diagnosis in patients and their families. Psychopathology. 2004;37:76–80

PII: S0006-3223(08)01481-9

doi: 10.1016/j.biopsych.2008.11.022

Biological Psychiatry
Volume 65, Issue 7 , Pages 600-606 , 1 April 2009

Article Tools

* Image Usage & Resolution